Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 2 April 2021. Rebecca Kelly Slaughter.

Executive Summary

The US Federal Trade Commission is trying to stop Illumina’s planned acquisition of Grail, because it could reduce patients’ access to multi-cancer screening tests. See what FTC chairwoman Rebecca Kelly Slaughter said about it here.

"[Multi-cancer early detection] is a game changer for cancer patients and their loved ones. If this acquisition is consummated, it would likely reduce innovation in this critical area of health care, diminish the quality of [these] tests, and make them more expensive.” – Rebecca Kelly Slaughter, chairwoman, FTC

Click here for a free trial of Medtech Insight

Related Content

Topics

UsernamePublicRestriction

Register

MT143726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel